Form 4: Olema Pharmaceuticals Chief Medical Officer Exercises Stock Options

Olema Pharmaceuticals' Chief Medical Officer, Naseem Zojwalla, exercised stock options for 14,000 shares at $4.87 per share on December 16, 2024.

Summary

• Naseem Zojwalla, the Chief Medical Officer of Olema Pharmaceuticals, exercised stock options to acquire 14,000 shares of common stock.
• The transaction occurred on December 16, 2024, at an exercise price of $4.87 per share.
• Following this transaction, Mr. Zojwalla directly owns 129,509 shares of common stock and 112,840 stock options.
• The stock options vest over time, with 25% vesting on February 1, 2024, and the remainder vesting monthly.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation, which is generally neutral to positive. The exercise of options indicates confidence in the company's future.

Industry Context

This is a routine filing related to executive compensation and is common for publicly traded companies. It reflects the standard practice of granting stock options to key personnel.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for executives in the biotechnology and pharmaceutical industries.
• The vesting schedule of 25% initially and then monthly is a typical structure for these types of grants.
• Companies like Amgen, Gilead, and Regeneron also use stock options as part of their executive compensation packages.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it is a standard part of executive compensation.
• The exercise of options by the Chief Medical Officer could be seen as a positive sign of confidence in the company's prospects.

Key Dates

Keywords

stock options, insider trading, executive compensation, beneficial ownership, Olema Pharmaceuticals, OLMA